Navigation Links
AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
Date:5/21/2008

AMSTERDAM, The Netherlands, May 22 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from La Sapienza University in Rome, Italy, to their advanced small nuclear RNA (snRNA)-based exon-skipping technology for the treatment of Duchenne muscular dystrophy (DMD). The combination with AMT's proprietary adeno-associated virus (AAV) gene therapy platform potentially makes up a long-term treatment for this seriously debilitating disease with a single administration of the product.

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy, caused by mutations in the dystrophin gene (essential for muscle function) is a severely debilitating neuromuscular disease. It affects young children, is progressive and leads to death in young adulthood. In the USA and Europe about 120,000 people suffer from it. Today, there is no treatment to prevent the fatal outcome.

The group of Prof. Irene Bozzoni at La Sapienza has done seminal work to develop a treatment for DMD. Using adeno-associated viral vectors, AMT's gene therapy platform of choice, and an exon-skipping snRNA program Bozzoni and co-workers demonstrated long term systemic and therapeutic effect in animals after a single administration[1]. One of the important advantages of the Bozzoni technology is that a single systemic delivery of the AAV vector containing the required antisense RNA-coding construct will result in long-term treatment of Duchenne muscular dystrophy.

Formalizing relationship with leading RNA research group of prof. Irene Bozzoni

Ronald Lorijn, CEO of AMT said: "We are very excited to have inlicenced an exciting therapeutic approach, which has shown to provide a life-long cure in rodents suffering from Duchenne's disease. In Duchenne's disease in particular the combined application of snRNA and AAV vectors has shown tremendous promise. Access to La Sapienza's RNA technology perfectly complements our gene and vector therapy platform. It adds a project to AMT's R&D pipeline that will start its pre-clinical phase this year."

Exon skipping in DMD

Exon skipping is a technology to neutralize genetic defects by preventing the faulty parts of the gene being used. At the cellular level, a molecule called messenger RNA (mRNA) reads off (transcribes) the protein instructions from the gene. It then transports these instructions to the ribosomes in the cell where the protein is assembled. Messenger RNA is not a transcript of the complete gene sequence, but only of the exons, which are the sections of the gene that code for a portion of the protein. If one of the exons contains an error, this process may be halted, and the production of the full-length dystrophin protein cannot take place. However, when the faulty exon is eliminated (i.e. skipped), protein synthesis does take place and leads to a functional, albeit shorter, dystrophin protein. By using the exon-skipping technique the mutated exons in the dystrophin mRNA that contain errors are "skipped" and as a result the muscle cells are able to produce functional dystrophin protein.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Accesses up to $30 Million of Working Capital
2. DolmatConnell & Partners 2008 Studies of CEO and CFO Compensation in the 100 Largest High Technology and Life Science Companies Show Dramatically Improving Link Between Pay and Performance
3. Naviscan PET Systems and Rockville PET Imaging Partner to Bring a New Breast Imaging Technology to New York
4. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
5. NASA Nanotechnology-Based Biosensor Helps Detect Biohazards
6. eResearchTechnology Announces Resignation of its CFO
7. American Oriental Bioengineering Forms Science and Technology Advisory Committee
8. Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007
9. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
10. Kiwa Bio-Tech in Collaboration Discussions with Beijing Hai Xin Science and Technology Co., Ltd.
11. Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North Carolina, ... Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the ...
Breaking Biology Technology:
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):